Overall been very disappointed about the lack of cross country help. Even if ignore basic humanitarian issues a raging outbreak anywhere is not good for anyone.
View: https://twitter.com/d_jaishankar/status/1385577997919469569?s=21
Current Affairs Coronavirus Thread - Serious stuff !!!
- Thread starter bullybeef
- Start date
- Status
View: https://twitter.com/d_jaishankar/status/1385577997919469569?s=21
davek
Player Valuation: £150m
I;m not buying into the vaccines being a release from this virus. That's for the birds. It'll be back and it'll be as bad as ever.
But every single piece of data shows that the vaccines stop deaths and stop hospital admissions, across the board.
How will it come back?
And don't give me the variant bull, all they have done is chat variants, screw them.
Alan Whittle
Player Valuation: £70m
I think I’ve proved I’m enough of a clot already!
Alan Whittle
Player Valuation: £70m
Veery interesting....
Alan Whittle
Player Valuation: £70m
Feel more of a Dustin Gee most days...
Not great is it?
That's not the case with America though. They're sat on about 30 million doses of the AZ vaccine that will never be used. They're also banning the export of vital raw materials that would actually help other countries make vaccines themselves. That the company who are supposedly the cheerleader of free trade is doing this is another matter.
davek
Player Valuation: £150m
Risks to herd immunity
Herd immunity requires that enough people be simultaneously immune to SARS-CoV-2 to prevent widespread ongoing transmission. While data indicate that the most likely scenario is to reach this state on the timelines described above, five risks could delay progress.First, vaccine adoption may prove lower than expected. That could happen if a real or perceived safety issue increases hesitancy or if younger populations see little reason to be vaccinated once older cohorts are protected and a transition toward normalcy is well underway. Second, herd immunity relies on the efficacy of vaccines at reducing transmission (rather than the usually reported efficacy at preventing disease in the vaccinated person). While initial data suggest that COVID-19 vaccines do block significant transmission,25 the efficacy rate may not prove high enough to drive herd immunity. Third, the duration of vaccine-mediated immunity may prove shorter than anticipated, making it hard to reach the necessary threshold for simultaneous immunity. Fourth, supply-chain disruptions and delays are real, and could produce supply shocks and interfere with timelines. Fifth, and most concerning, variants that reduce the efficacy of vaccines or the benefits of natural immunity may spread widely. Some initial data offer concerning evidence that B.1.351 and P.1 may be examples of such variants, although recent Novavax data (with a small sample size) offer some reassurance that its vaccine is effective against severe disease caused by B1.351.26 Similarly, limited data from the Pfizer-BioNTech and AstraZeneca vaccines show evidence of some protection against P.1.27
When will the COVID-19 pandemic end?
McKinsey’s evolving perspectives on when will the COVID-19 pandemic end in the United States updated to examine how timing will vary around the world.
Risks to herd immunity
Herd immunity requires that enough people be simultaneously immune to SARS-CoV-2 to prevent widespread ongoing transmission. While data indicate that the most likely scenario is to reach this state on the timelines described above, five risks could delay progress.
First, vaccine adoption may prove lower than expected. That could happen if a real or perceived safety issue increases hesitancy or if younger populations see little reason to be vaccinated once older cohorts are protected and a transition toward normalcy is well underway. Second, herd immunity relies on the efficacy of vaccines at reducing transmission (rather than the usually reported efficacy at preventing disease in the vaccinated person). While initial data suggest that COVID-19 vaccines do block significant transmission,25 the efficacy rate may not prove high enough to drive herd immunity. Third, the duration of vaccine-mediated immunity may prove shorter than anticipated, making it hard to reach the necessary threshold for simultaneous immunity. Fourth, supply-chain disruptions and delays are real, and could produce supply shocks and interfere with timelines. Fifth, and most concerning, variants that reduce the efficacy of vaccines or the benefits of natural immunity may spread widely. Some initial data offer concerning evidence that B.1.351 and P.1 may be examples of such variants, although recent Novavax data (with a small sample size) offer some reassurance that its vaccine is effective against severe disease caused by B1.351.26 Similarly, limited data from the Pfizer-BioNTech and AstraZeneca vaccines show evidence of some protection against P.1.27
When will the COVID-19 pandemic end?
McKinsey’s evolving perspectives on when will the COVID-19 pandemic end in the United States updated to examine how timing will vary around the world.www.mckinsey.com
I never mentioned herd immunity.
Vaccines Dave, that's what is winning us this war.
Some people genuinely want to be locked in their house by dear leader government forever.
What you really mean, is you want the state to continue to have as much control of our lives as possible and we should all live in some quasi state controlled society.
All in all you’ve had a bad week really. The AZ gnats piss, disaster vaccine, has got the virus on the run in the U.K. and Brands has got himself a nice new, shiny three year contract.
Put the Morning Star away comrade, it’s over.
And nor should they be currently.
As I've said, I was pushing for lockdowns HARD when they were needed and my God were they needed, but now, the suns out, the cases are very low, the deaths are also, enjoy life.
I have gladly obliged by going the pub 4 times this week.
Oh, look another carefully selected domesday article, from his big book of domesday articles lol
- Status